CN112362872A - Pancreatic cancer tumor marker and application thereof - Google Patents
Pancreatic cancer tumor marker and application thereof Download PDFInfo
- Publication number
- CN112362872A CN112362872A CN202011160471.0A CN202011160471A CN112362872A CN 112362872 A CN112362872 A CN 112362872A CN 202011160471 A CN202011160471 A CN 202011160471A CN 112362872 A CN112362872 A CN 112362872A
- Authority
- CN
- China
- Prior art keywords
- pancreatic cancer
- tumor marker
- cancer tumor
- application
- mir
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010061902 Pancreatic neoplasm Diseases 0.000 title claims abstract description 152
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 title claims abstract description 152
- 201000002528 pancreatic cancer Diseases 0.000 title claims abstract description 152
- 208000008443 pancreatic carcinoma Diseases 0.000 title claims abstract description 152
- 239000000439 tumor marker Substances 0.000 title claims abstract description 70
- 239000003112 inhibitor Substances 0.000 claims abstract description 23
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 11
- 239000002773 nucleotide Substances 0.000 claims description 24
- 125000003729 nucleotide group Chemical group 0.000 claims description 24
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 239000003153 chemical reaction reagent Substances 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 12
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- 238000001514 detection method Methods 0.000 abstract description 17
- 238000013399 early diagnosis Methods 0.000 abstract description 15
- 210000004027 cell Anatomy 0.000 description 52
- 108091024436 Homo sapiens miR-6779 stem-loop Proteins 0.000 description 43
- 108090000623 proteins and genes Proteins 0.000 description 33
- 230000014509 gene expression Effects 0.000 description 27
- 241000282414 Homo sapiens Species 0.000 description 17
- 229920002477 rna polymer Polymers 0.000 description 14
- 238000003757 reverse transcription PCR Methods 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 6
- 210000001808 exosome Anatomy 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000011529 RT qPCR Methods 0.000 description 4
- 101150018082 U6 gene Proteins 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 239000012097 Lipofectamine 2000 Substances 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 201000010985 invasive ductal carcinoma Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 210000000277 pancreatic duct Anatomy 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention provides a pancreatic cancer tumor marker, wherein the RNA sequence of the pancreatic cancer tumor marker is shown as SEQ ID NO. 1. Also provides the application of the pancreatic cancer tumor marker. Also provides a detection primer pair of the pancreatic cancer tumor marker and application thereof. Also provides an accelerant of the pancreatic cancer tumor marker and application thereof. Also provides an inhibitor of the pancreatic cancer tumor marker and application thereof. The pancreatic cancer tumor marker disclosed by the invention can be used for simply, conveniently, accurately and quickly diagnosing pancreatic cancer, improving the early diagnosis level of pancreatic cancer and being suitable for large-scale popularization and application.
Description
Technical Field
The invention relates to the technical field of biological medicines, in particular to the technical field of tumor markers, and particularly relates to a pancreatic cancer tumor marker and application thereof.
Background
Pancreatic cancer is a highly invasive, highly malignant, difficult to diagnose and treat malignant neoplasm of the digestive tract, and about 90% of it is ductal adenocarcinoma originating from the epithelium of the glandular duct. Its morbidity and mortality has increased dramatically in recent years. The treatment of pancreatic cancer is mainly a comprehensive treatment combining surgery, chemotherapy and radiotherapy, the 5-year survival rate of the pancreatic cancer is less than 1 percent, and the pancreatic cancer is one of the worst malignant tumors. The early diagnosis rate of pancreatic cancer is low, the operative mortality rate is high, and the cure rate is low. The incidence rate of pancreatic cancer is higher for men than for women, the ratio of men to women is 1.5-2: 1, male patients are more common than for women before menopause, and the incidence rate of postmenopausal women is similar to that of men.
Therefore, early diagnosis is particularly important for the treatment and prognosis of pancreatic cancer, and peripheral blood detection is the most common and easily popularized diagnostic method. The pancreatic cancer diagnostic marker commonly used in clinic at present, such as CA19-9, plays an important role in diagnosing the occurrence of tumor and monitoring the recurrence thereof. However, the specificity and sensitivity of these markers are often too low to meet clinical needs, and a relatively sensitive method is still lacking, especially in terms of early diagnostic value. Therefore, finding a novel pancreatic cancer tumor marker with high sensitivity and specificity would be the key to increasing the level of early diagnosis of pancreatic cancer.
Therefore, it is desirable to provide a tumor marker for pancreatic cancer, which can make diagnosis of pancreatic cancer simple, accurate and rapid and can improve the level of early diagnosis of pancreatic cancer.
Disclosure of Invention
In order to overcome the defects in the prior art, an object of the present invention is to provide a pancreatic cancer tumor marker, which can make diagnosis of pancreatic cancer simple, accurate and rapid, improve early diagnosis level of pancreatic cancer, and is suitable for large-scale popularization and application.
The invention also aims to provide a pair of detection primer pairs for pancreatic cancer tumor markers, which can simply, rapidly and accurately detect the pancreatic cancer tumor markers, improve the early diagnosis level of pancreatic cancer and is suitable for large-scale popularization and application.
The other purpose of the present invention is to provide a promoter for pancreatic cancer tumor markers, which can promote the expression of the pancreatic cancer tumor markers, further inhibit the growth of pancreatic cancer tumor cells, and is suitable for large-scale popularization and application.
The invention also aims to provide an inhibitor of the pancreatic cancer tumor marker, which can inhibit the expression of the pancreatic cancer tumor marker, further promote the growth of normal pancreatic cells, and is suitable for large-scale popularization and application.
The invention also aims to provide application of the pancreatic cancer tumor marker as a pancreatic cancer diagnostic reagent, which can enable pancreatic cancer to be diagnosed simply, accurately and quickly, improve early diagnosis level of pancreatic cancer, and is suitable for large-scale popularization and application.
The invention also aims to provide application of the detection primer pair of the pancreatic cancer tumor marker as a pancreatic cancer diagnostic reagent, which can simply, conveniently, rapidly and accurately detect the pancreatic cancer tumor marker, improve the early diagnosis level of pancreatic cancer and is suitable for large-scale popularization and application.
The invention also aims to provide application of the promoter for the pancreatic cancer tumor marker in serving as a pancreatic cancer treatment drug, which can promote the expression of the pancreatic cancer tumor marker so as to inhibit the growth of pancreatic cancer tumor cells, and is suitable for large-scale popularization and application.
The invention also aims to provide application of the inhibitor of the pancreatic cancer tumor marker in serving as a pancreatic cancer treatment drug, which can inhibit the expression of the pancreatic cancer tumor marker so as to promote the growth of normal pancreatic cells, and is suitable for large-scale popularization and application.
In order to achieve the above objects, in a first aspect of the present invention, there is provided a pancreatic cancer tumor marker, characterized in that the RNA sequence of the pancreatic cancer tumor marker is represented by SEQ ID No. 1.
In a second aspect of the present invention, a pair of the above-mentioned detection primer pairs for pancreatic cancer tumor markers is provided, wherein the detection primer pairs for pancreatic cancer tumor markers have the nucleotide sequences shown in SEQ ID NO. 3 and SEQ ID NO. 4.
In a third aspect of the present invention, there is provided an accelerator for a tumor marker of pancreatic cancer as described above, wherein the inhibitor for a tumor marker of pancreatic cancer has a nucleotide sequence shown in SEQ ID NO. 5.
In a fourth aspect of the present invention, there is provided an inhibitor of the above pancreatic cancer tumor marker, which is characterized in that the inhibitor of the pancreatic cancer tumor marker has a nucleotide sequence shown in SEQ ID NO. 6.
In a fifth aspect of the present invention, there is provided a use of the above-mentioned pancreatic cancer tumor marker as a pancreatic cancer diagnostic reagent.
In a sixth aspect of the present invention, an application of the detection primer pair for pancreatic cancer tumor markers as a pancreatic cancer diagnostic reagent is provided.
In a seventh aspect of the present invention, there is provided a use of the promoter for a tumor marker of pancreatic cancer as a medicament for treating pancreatic cancer.
In the eighth aspect of the present invention, there is provided a use of the above-mentioned inhibitor for a tumor marker of pancreatic cancer as a therapeutic agent for pancreatic cancer.
The invention has the beneficial effects that:
a. the RNA sequence of the pancreatic cancer tumor marker is shown as SEQ ID NO. 1, the pancreatic cancer marker can be used for simply, conveniently, accurately and quickly diagnosing pancreatic cancer, improving the early diagnosis level of pancreatic cancer, and is suitable for large-scale popularization and application.
b. The detection primer pair of the pancreatic cancer tumor marker has the nucleotide sequence shown in SEQ ID NO. 3 and the nucleotide sequence shown in SEQ ID NO. 4, can simply, conveniently, quickly and accurately detect the pancreatic cancer tumor marker, improves the early diagnosis level of pancreatic cancer, and is suitable for large-scale popularization and application.
c. The promoter of the pancreatic cancer tumor marker has a nucleotide sequence shown in SEQ ID NO. 5, can promote the expression of the pancreatic cancer tumor marker, further inhibits the growth of pancreatic cancer tumor cells, and is suitable for large-scale popularization and application.
d. The inhibitor of the pancreatic cancer tumor marker has a nucleotide sequence shown in SEQ ID NO. 6, can inhibit the expression of the pancreatic cancer tumor marker, further promotes the growth of normal pancreatic cells, and is suitable for large-scale popularization and application.
e. The pancreatic cancer tumor marker disclosed by the invention is applied to serving as a pancreatic cancer diagnostic reagent, can be used for simply, conveniently, accurately and quickly diagnosing pancreatic cancer, improving the early diagnosis level of pancreatic cancer, and is suitable for large-scale popularization and application.
f. The application of the detection primer pair of the pancreatic cancer tumor marker in serving as a pancreatic cancer diagnostic reagent can simply, conveniently, quickly and accurately detect the pancreatic cancer tumor marker, improve the early diagnosis level of pancreatic cancer, and is suitable for large-scale popularization and application.
g. The promoter for the pancreatic cancer tumor marker can promote the expression of the pancreatic cancer tumor marker and further inhibit the growth of pancreatic cancer tumor cells when being applied to a pancreatic cancer treatment drug, and is suitable for large-scale popularization and application.
h. The inhibitor of the pancreatic cancer tumor marker can inhibit the expression of the pancreatic cancer tumor marker and further promote the growth of normal pancreatic cells when being applied to a pancreatic cancer treatment drug, and is suitable for large-scale popularization and application.
These and other objects, features and advantages of the present invention will become more fully apparent from the following detailed description, the accompanying drawings and the appended claims, wherein like reference numerals refer to like parts throughout the several views, and wherein like reference numerals refer to like parts throughout the several views.
Drawings
FIG. 1 is a schematic diagram of the quantitative RT-PCR method for detecting the expression of hsa-miR-6779-5p gene in blood samples of pancreatic cancer patients and blood samples of healthy persons.
FIG. 2 is a schematic diagram of the detection of the expression of hsa-miR-6779-5p gene in pancreatic cancer cell lines and human normal pancreatic ductal epithelial cells HPDE by quantitative RT-PCR, wherein: p < 0.0001.
FIG. 3 is a schematic diagram of the detection of the expression of hsa-miR-6779-5p gene in the pancreatic cancer cell line BxPC-3 overexpressing hsa-miR-6779-5p gene (A and B) and in normal HPDE cells inhibiting the expression of hsa-miR-6779-5p gene (C and D) by quantitative RT-PCR, in which: p < 0.0001.
FIG. 4 is a schematic diagram showing the cell proliferation potency changes of pancreatic cancer cell line BxPC-3 overexpressing hsa-miR-6779-5p gene and normal HPDE cells inhibiting the expression of hsa-miR-6779-5p gene.
Detailed Description
In order to make the diagnosis of pancreatic cancer simple, convenient, accurate and rapid and improve the early diagnosis level of pancreatic cancer, the invention provides a pancreatic cancer tumor marker, and the RNA sequence of the pancreatic cancer tumor marker is shown as SEQ ID NO. 1. The pancreatic cancer tumor marker is hsa-miR-6779-5p gene.
The invention also provides a pair of detection primer pairs of the pancreatic cancer tumor marker, and the detection primer pairs of the pancreatic cancer tumor marker have a nucleotide sequence shown as SEQ ID NO. 3 and a nucleotide sequence shown as SEQ ID NO. 4.
The invention also provides an accelerant of the pancreatic cancer tumor marker, and an inhibitor of the pancreatic cancer tumor marker has a nucleotide sequence shown as SEQ ID NO. 5.
The invention also provides an inhibitor of the pancreatic cancer tumor marker, which has a nucleotide sequence shown as SEQ ID NO. 6.
The invention also provides application of the pancreatic cancer tumor marker in serving as a pancreatic cancer diagnostic reagent.
The invention also provides application of the detection primer pair of the pancreatic cancer tumor marker in serving as a pancreatic cancer diagnostic reagent.
The invention also provides application of the promoter of the pancreatic cancer tumor marker in serving as a pancreatic cancer treatment drug.
The invention also provides application of the inhibitor of the pancreatic cancer tumor marker in serving as a pancreatic cancer treatment drug.
In order to clearly understand the technical contents of the present invention, the following examples are given in detail. It should be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention. Experimental procedures without specific conditions noted in the following examples, generally followed by conventional conditions, such as Sambrook et al, molecular cloning: the conditions described in the Laboratory Manual (New York: Cold Spring Harbor Laboratory Press,1989), or according to the manufacturer's recommendations. Example 1 quantitative RT-PCR detection of expression of hsa-miR-6779-5p Gene in blood samples from patients with pancreatic cancer and blood samples from healthy persons
1. Specimen source: after the consent of the patients and healthy persons was obtained, blood samples of 19 pancreatic cancer patients and 10 healthy persons were collected, the ages and sexes of the healthy persons were matched with those of the pancreatic cancer patients, and the blood sampling time was in the early morning in an empty stomach state.
2. Extraction of ribonucleic acid (RNA): total RNA was extracted using Trizol kit (Invitrogen), the extraction method referring to the Trizol kit instructions. When RNA is to be used, the following method may be used to precipitate RNA: NaAc was added to 0.3M and centrifuged at 12,000 Xg for 5 minutes.
3. Synthesis of cDNA:
(1) adding 4 muL (0.5 mug/muL) of template RNA, 2 muL of 20 pmol/muL of RT primer of hsa-miR-6779-5p gene (shown as the nucleotide sequence of SEQ ID NO: 2) and 20 pmol/muL of RT primer of U6 gene (also shown as the reverse amplification primer of U6 gene, namely the nucleotide sequence shown as SEQ ID NO: 8) into an ice-bath centrifuge tube, uniformly mixing, and centrifuging for 3-5 seconds;
(2) water bath at 70 ℃ for 5 minutes and ice bath for 30 seconds;
(3) adding 5 XM-MLV reverse transcriptase reaction solution 4 μ L, RNase inhibitor 1 μ L, dNTP 2 μ L (100mM), and mixing;
(4) water bath at 37 ℃ for 5 minutes, adding 1 mu L M-MLV reverse transcriptase (200 enzyme activity units/. mu.L), and mixing uniformly;
(5) water bath at 37 ℃ for 1 hour;
(6) the reaction was terminated at 70 ℃ for 10 minutes, the product was placed on ice for the next PCR experiment, and the remaining was stored at-70 ℃.
4. Primer design and amplification for quantitative RT-PCR
A primer pair is designed according to the RNA sequence and the RT primer sequence of the hsa-miR-6779-5p gene shown in SEQ ID NO. 1, and is respectively shown as the nucleotide sequence shown in SEQ ID NO. 3 and the nucleotide sequence shown in SEQ ID NO. 4.
In addition, U6 is used as an internal control, and the amplification primer pair is respectively shown as the nucleotide sequence shown in SEQ ID NO. 7 and the nucleotide sequence shown in SEQ ID NO. 8.
Reagent of experimental instrument: thermal Cycler dice Real Time System TP800, Takara; premix Ex TaqTM, Takara.
Reaction system of PCR: total volume 20. mu.L, SYBR Premix Ex Taq 10. mu.L, top and bottom0.4. mu.L each of the primers (10. mu. mol/L), cDNA 1. mu.L, ddH2O8.2 mu L, mixing the reagent evenly, centrifuging and putting the reagent into a PCR instrument for amplification reaction. The PCR conditions were 94 ℃ for 4 min; 30s at 94 ℃, 20s at 60 ℃ and 40 cycles. The PCR amplification products were detected by agarose gel electrophoresis, and the results are shown in FIG. 1.
5. The experimental results are as follows: as can be seen from the results in FIG. 1, the expression level of the hsa-miR-6779-5p gene in the blood sample of pancreatic cancer patients is obviously lower than that in the blood sample of healthy people, and the p value is less than 0.05 (statistically significant) through a t test.
Example 2 quantitative RT-PCR detection of expression of hsa-miR-6779-5p gene in pancreatic cancer cell lines and cell supernatant exosomes
The expression of hsa-miR-6779-5p gene in human pancreatic cancer cell strains AsPC-1, BxPC-3, CFPAC-1, HPAF-II, MIA PaCa-2, PANC-1 and human normal pancreatic duct epithelial cell HPDE and the expression in cell supernatant exosomes are detected by quantitative RT-PCR. Wherein the cell strain is derived from Shanghai cell bank of Chinese academy of sciences.
The RNA of the cell line and the exosome RNA of the cell supernatant were extracted according to the method described in example 1, and the cDNA was synthesized by reverse transcription, and PCR reaction was performed according to the method described in example 1 using U6 as an internal control and the cDNA of the exosome of the different cell lines and the cell supernatant as a template, and the PCR amplification product was detected by agarose gel electrophoresis, and the results are shown in FIG. 2.
As can be seen from the results in FIG. 2, the hsa-miR-6779-5p gene is expressed very little in AsPC-1, BxPC-3, MIA PaCa-2 and PANC-1 and is expressed less in CFPAC-1 and HPAF-II. The hsa-miR-6779-5p gene has very low expression in cell supernatant exosomes of AsPC-1, BxPC-3, MIA PaCa-2 and PANC-1, and has low expression in cell supernatant exosomes of CFPAC-1 and HPAF-II.
Example 3 overexpression of hsa-miR-6779-5p in pancreatic cancer cell line BxPC-3 and inhibition of expression of hsa-miR-6779-5p and change in proliferation capacity of cells after expression of hsa-miR-6779-5p in normal pancreatic ductal epithelial cells HPDE
Aiming at the mRNA of the hsa-miR-6779-5p gene, designing and synthesizing an hsa-miR-6779-5p mimics sequence and an hsa-miR-6779-5p inhibitor sequence, which are respectively shown as a nucleotide sequence shown in SEQ ID NO. 5 and a nucleotide sequence shown in SEQ ID NO. 6; unrelated sequences NC mimics and NC inhibitor are respectively set as negative controls, and are respectively shown as a nucleotide sequence shown in SEQ ID NO. 9 and a nucleotide sequence shown in SEQ ID NO. 10.
Using liposome (Lipofectamine 2000) transfection reagent, hsa-miR-6779-5p mimics and NC mimics were transfected into BxPC-3 cells at a final concentration of 50nmol/L and hsa-miR-6779-5p inhibitor and NC inhibitor were transfected into HPDE cells (supplied from Shanghai cell Bank of China academy of sciences) at a final concentration of 50nmol/L, respectively, and cultured with DMEM containing 10% fetal bovine serum. RNA of different cell lines was extracted according to the method described in example 1, cDNA was synthesized by reverse transcription, and the expression of hsa-miR-6779-5p gene in pancreatic cancer cell line BxPC-3 and normal HPDE cells was detected by quantitative RT-PCR assay using U6 as an internal control and cDNA of different cell lines as a template according to the method described in example 1, and the results are shown in FIG. 3.
As can be seen from the results of FIGS. 3 to 4, compared with the control group (NC mimics), the hsa-miR-6779-5p mimics can effectively promote the mRNA level of the hsa-miR-6779-5p gene in the pancreatic cancer cell line BxPC-3, and can inhibit the growth of the pancreatic cancer cell line BxPC-3 cells, the survival rate of the pancreatic cancer cells is obviously lower than that of the cells of the control group, and the results show that the expression up-regulation of the human hsa-miR-6779-5p gene can inhibit the growth of the pancreatic cancer cells to a certain extent. Compared with a control group (NC inhibit), the hsa-miR-6779-5p inhibit can effectively inhibit the mRNA level of the hsa-miR-6779-5p gene in the HPDE cell, can promote the growth of the HPDE cell, has the survival rate obviously higher than that of the cell of the control group, and shows that the expression of the human hsa-miR-6779-5p gene is reduced and the growth of normal pancreatic cells can be promoted to a certain extent.
Therefore, the hsa-miR-6779-5p gene and the expression product thereof are used as markers for diagnosing pancreatic cancer, so that the pancreatic cancer can be diagnosed more accurately and quickly, and the hsa-miR-6779-5p gene and the expression product thereof are used as target genes for preparing medicaments for treating pancreatic cancer, so that new treatment targets and treatment ways are provided for treating pancreatic cancer.
In conclusion, the pancreatic cancer tumor marker disclosed by the invention can be used for simply, conveniently, accurately and quickly diagnosing pancreatic cancer, improving the early diagnosis level of pancreatic cancer and being suitable for large-scale popularization and application.
In this specification, the invention has been described with reference to specific embodiments thereof. It will, however, be evident that various modifications and changes may be made thereto without departing from the broader spirit and scope of the invention. The specification and drawings are, accordingly, to be regarded in an illustrative rather than a restrictive sense.
Sequence listing
<110> Shanghai Youlika information technology Co., Ltd
<120> pancreatic cancer tumor marker and application thereof
<160> 10
<210> 1
<211> 21
<212> RNA
<213> human (Homo sapiens)
<220>
<221> misc_RNA
<222> (1)...(21)
<223> RNA sequence of human hsa-miR-6779-5p gene
<400> 1
cugggagggg cuggguuugg c 21
<210> 2
<211> 50
<212> DNA
<213> Artificial sequence
<220>
<221> misc_feature
<222> (1)...(50)
<223> reverse transcription primer of RNA sequence of human hsa-miR-6779-5p gene
<400> 2
gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgacgccaaa 50
<210> 3
<211> 21
<212> RNA
<213> Artificial sequence
<220>
<221> misc_feature
<222> (1)...(21)
<223> qPCR forward primer for amplifying human hsa-miR-6779-5p gene
<400> 3
aacacaccug ggaggggcug g 21
<210> 4
<211> 19
<212> DNA
<213> Artificial sequence
<220>
<221> misc_feature
<222> (1)...(19)
<223> qPCR reverse primer for amplifying human hsa-miR-6779-5p gene
<400> 4
gtcgtatcca gtgcagggt 19
<210> 5
<211> 21
<212> RNA
<213> Artificial sequence
<220>
<221> misc_feature
<222> (1)...(21)
<223> mimics sequence of RNA sequence of human hsa-miR-6779-5p gene
<400> 5
cugggagggg cuggguuugg c 21
<210> 6
<211> 21
<212> RNA
<213> Artificial sequence
<220>
<221> misc_feature
<222> (1)...(21)
<223> inhibitor sequence of RNA sequence of human hsa-miR-6779-5p gene
<400> 6
gccaaaccca gaaaauccca g 21
<210> 7
<211> 17
<212> DNA
<213> Artificial sequence
<220>
<221> misc_feature
<222> (1)...(17)
<223> qPCR forward primer for amplifying human U6 gene
<400> 7
ctcgcttcgg cagcaca 17
<210> 8
<211> 20
<212> DNA
<213> Artificial sequence
<220>
<221> misc_feature
<222> (1)...(20)
<223> qPCR reverse primer for amplifying human U6 gene
<400> 8
<210> 9
<211> 21
<212> DNA
<213> Artificial sequence
<220>
<221> misc_feature
<222> (1)...(21)
<223> NC mimics sequence of human hsa-miR-6779-5p gene
<400> 9
uucuccgaac gugucacgut t 21
<210> 10
<211> 21
<212> RNA
<213> Artificial sequence
<220>
<221> misc_feature
<222> (1)...(21)
<223> NC inhibitor sequence of human hsa-miR-6779-5p gene
<400> 10
uucuccgaac gugucacgut t 21
Claims (8)
1. A pancreatic cancer tumor marker is characterized in that the RNA sequence of the pancreatic cancer tumor marker is shown as SEQ ID NO. 1.
2. The pair of primers for detecting pancreatic cancer tumor markers according to claim 1, wherein the pair of primers for detecting pancreatic cancer tumor markers has the nucleotide sequence shown in SEQ ID NO. 3 and the nucleotide sequence shown in SEQ ID NO. 4.
3. The promoter for a tumor marker of pancreatic cancer according to claim 1, wherein said promoter for a tumor marker of pancreatic cancer has a nucleotide sequence shown in SEQ ID NO. 5.
4. The inhibitor of pancreatic cancer tumor marker according to claim 1, wherein said inhibitor of pancreatic cancer tumor marker has a nucleotide sequence shown in SEQ ID NO. 6.
5. The pancreatic cancer tumor marker of claim 1 for use as a pancreatic cancer diagnostic reagent.
6. The use of the primer pair for detecting a tumor marker of pancreatic cancer according to claim 2 as a diagnostic reagent for pancreatic cancer.
7. The use of the promoter for a tumor marker of pancreatic cancer according to claim 3 as a therapeutic agent for pancreatic cancer.
8. The use of the inhibitor of a tumor marker for pancreatic cancer according to claim 4 as a therapeutic agent for pancreatic cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011160471.0A CN112362872A (en) | 2020-10-27 | 2020-10-27 | Pancreatic cancer tumor marker and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011160471.0A CN112362872A (en) | 2020-10-27 | 2020-10-27 | Pancreatic cancer tumor marker and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112362872A true CN112362872A (en) | 2021-02-12 |
Family
ID=74510577
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011160471.0A Pending CN112362872A (en) | 2020-10-27 | 2020-10-27 | Pancreatic cancer tumor marker and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112362872A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113151464A (en) * | 2021-03-29 | 2021-07-23 | 武汉博越致和生物科技有限公司 | Method for diagnosing pancreatic cancer by miRNA detection and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2951008A1 (en) * | 2014-06-11 | 2015-12-17 | Toray Industries, Inc. | Biliary tract cancer detection kit or device, and detection method |
| CN106459961A (en) * | 2014-05-30 | 2017-02-22 | 东丽株式会社 | Pancreatic cancer detection kit, device, and detection method |
| WO2019163900A1 (en) * | 2018-02-22 | 2019-08-29 | 国立大学法人大阪大学 | Analysis/diagnosis method utilizing rna modification |
-
2020
- 2020-10-27 CN CN202011160471.0A patent/CN112362872A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106459961A (en) * | 2014-05-30 | 2017-02-22 | 东丽株式会社 | Pancreatic cancer detection kit, device, and detection method |
| CA2951008A1 (en) * | 2014-06-11 | 2015-12-17 | Toray Industries, Inc. | Biliary tract cancer detection kit or device, and detection method |
| WO2019163900A1 (en) * | 2018-02-22 | 2019-08-29 | 国立大学法人大阪大学 | Analysis/diagnosis method utilizing rna modification |
Non-Patent Citations (2)
| Title |
|---|
| MOTOHIRO KOJIMA等: "MicroRNA Markers for the Diagnosis of Pancreatic and Biliary-Tract Cancers", PLOS ONE, vol. 10, no. 2, pages 0118220 * |
| 张艺璇等: "外泌体在胰腺癌诊断中的研究进展", 胃肠病学, vol. 25, no. 7, pages 441 - 444 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113151464A (en) * | 2021-03-29 | 2021-07-23 | 武汉博越致和生物科技有限公司 | Method for diagnosing pancreatic cancer by miRNA detection and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107881241B (en) | Application of gene marker in diagnosis and treatment of breast cancer | |
| CN107760784B (en) | Application of circular RNA circ-FOXP1 | |
| CN113462780B (en) | Marker and kit for auxiliary diagnosis of prostate cancer | |
| CN113201591B (en) | Application of long-chain non-coding RNA and inhibitor thereof in preventing and treating breast cancer | |
| CN111304326B (en) | Reagent for detecting and targeting lncRNA biomarker and application of reagent in hepatocellular carcinoma | |
| CN107519193B (en) | Molecular diagnostic marker for early stage esophageal squamous carcinoma and application thereof | |
| CN113278698A (en) | Application of annular RNAcir 0001610 and expression product thereof in medicines for diagnosing and treating bladder cancer | |
| CN110201172B (en) | Application of YY1 expression inhibitor in preparation of medicine for treating breast cancer | |
| CN111647660B (en) | Application of Linc01559 in diagnosis and treatment of gastric cancer | |
| CN112362872A (en) | Pancreatic cancer tumor marker and application thereof | |
| CN113718035A (en) | Application of circular RNA hsa _ circ _0003552 and kit for detecting circular RNA hsa _ circ _0003552 | |
| Su et al. | LncRNA MALAT1 promotes glioma cell growth through sponge miR-613 | |
| CN110699453B (en) | Bile duct cancer detection, treatment and prognosis target and application | |
| CN114921545B (en) | Application of human HHIPL1mRNA in non-small cell lung cancer diagnosis, prognosis evaluation and targeted therapy and kit | |
| CN110923324A (en) | Breast cancer miRNA marker and application thereof | |
| CN111154863B (en) | Application of lncRNA in preparation of product for diagnosing and/or treating osteoarthritis | |
| WO2022057193A1 (en) | Long-chain non-coding rna and use of inhibitor thereof | |
| CN109371136B (en) | Lung adenocarcinoma-related lncRNA and application thereof | |
| CN107184983B (en) | Diagnosis and treatment target for lung adenocarcinoma | |
| CN111088355A (en) | Molecular marker and kit for gastric cancer diagnosis | |
| CN111893112A (en) | Gastric cancer tumor marker and application thereof | |
| CN102816856B (en) | Application of DIAPH3 gene and expression product thereof | |
| CN111321226B (en) | Application of nucleic acid for detecting or inhibiting LncRNA PPP1R14B-AS1 | |
| CN108893537B (en) | C7ORF70 and application thereof | |
| CN111118154B (en) | Application of LINC01272 in preparation of tumor detection reagent and/or treatment drug |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |